GSK Korea introduces PritorPlus, combination therapy of telmisartan plus HCTZ

Published: 2003-10-16 06:57:00

Updated: 2003-10-16 06:57:00

GlaxoSmithKline Korea launched PritorPlus, a combination medication of telmisartan and diruretic hydrochlrorothiazide, in the domestic market on October 6 after approval from the Korea Food and Drug Administration last month. After approval from the US FDA in October 2000, PritorPlus has been mar...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK